300199 翰宇药业
已收盘 09-08 15:00:00
资讯
新帖
简况
翰宇药业（300199）披露全资子公司卡前列素氨丁三醇注射液获得药品注册证书，9月8日股价下跌2.35%
证券之星 · 17:53
翰宇药业（300199）披露全资子公司卡前列素氨丁三醇注射液获得药品注册证书，9月8日股价下跌2.35%
翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书
智通财经 · 09-07 16:51
翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书
翰宇药业：多肽原料药产能计划本年度内达到10吨级
证券之星 · 09-02
翰宇药业：多肽原料药产能计划本年度内达到10吨级
翰宇药业：公司产品布局会综合市场环境、供需情况、投入产出、业务战略方向等多重因素审慎考量
证券之星 · 09-02
翰宇药业：公司产品布局会综合市场环境、供需情况、投入产出、业务战略方向等多重因素审慎考量
翰宇药业：持续深耕GLP-1类降糖与减重相关产品
证券之星 · 09-02
翰宇药业：持续深耕GLP-1类降糖与减重相关产品
翰宇药业：持续跟踪行业形势变化
证券之星 · 09-02
翰宇药业：持续跟踪行业形势变化
翰宇药业(300199.SZ)：坪山分公司通过美国FDA现场检查
智通财经 · 09-02
翰宇药业(300199.SZ)：坪山分公司通过美国FDA现场检查
翰宇药业：坪山分公司第二次通过FDA现场检查
格隆汇 · 09-02
翰宇药业：坪山分公司第二次通过FDA现场检查
翰宇药业(300199)6月30日股东户数6.73万户，较上期减少31.87%
证券之星 · 08-21
翰宇药业(300199)6月30日股东户数6.73万户，较上期减少31.87%
翰宇药业最新公告：2026年半年度净利润同比增长62.72%
证券之星 · 08-20
翰宇药业最新公告：2026年半年度净利润同比增长62.72%
翰宇药业：利拉鲁肽注射液获新加坡卫生科学局批准上市
格隆汇 · 08-20
翰宇药业：利拉鲁肽注射液获新加坡卫生科学局批准上市
翰宇药业最新公告：与三生蔓迪签署司美格鲁肽注射液（血糖控制适应症）合作协议
证券之星 · 08-12
翰宇药业最新公告：与三生蔓迪签署司美格鲁肽注射液（血糖控制适应症）合作协议
翰宇药业（300199）披露替尔泊肽注射液首仿上市申请获得受理的公告，8月7日股价上涨8.45%
证券之星 · 08-07
翰宇药业（300199）披露替尔泊肽注射液首仿上市申请获得受理的公告，8月7日股价上涨8.45%
翰宇药业：替尔泊肽注射液首仿上市申请获受理
格隆汇 · 08-07
翰宇药业：替尔泊肽注射液首仿上市申请获受理
股市必读：翰宇药业（300199）新发布《关于HY3003多肽创新药临床前药效学研究结果的公告》
证券之星 · 07-31
股市必读：翰宇药业（300199）新发布《关于HY3003多肽创新药临床前药效学研究结果的公告》
翰宇药业(300199.SZ)：HY3003注射液已完成临床前动物药效学研究
智通财经 · 07-29
翰宇药业(300199.SZ)：HY3003注射液已完成临床前动物药效学研究
翰宇药业（300199）披露向激励对象首次授予限制性股票的公告，7月17日股价下跌12.38%
证券之星 · 07-17
翰宇药业（300199）披露向激励对象首次授予限制性股票的公告，7月17日股价下跌12.38%
翰宇药业（300199）披露2026年限制性股票激励计划内幕信息知情人买卖公司股票情况自查报告，7月13日股价下跌7.63%
证券之星 · 07-13
翰宇药业（300199）披露2026年限制性股票激励计划内幕信息知情人买卖公司股票情况自查报告，7月13日股价下跌7.63%
翰宇药业（300199）披露2026年半年度业绩预告，7月10日股价下跌1.32%
证券之星 · 07-10
翰宇药业（300199）披露2026年半年度业绩预告，7月10日股价下跌1.32%
翰宇药业最新公告：预计2026年半年度净利润同比增长54.67%-68.42%
证券之星 · 07-10
翰宇药业最新公告：预计2026年半年度净利润同比增长54.67%-68.42%
加载更多
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。公司共获得国内专利四百余项，国际专利数十项，各类多肽药物批件、新药证书和临床批件，配备国际领先的研发实验室及300余台（套）高端设备（如全自动合成系统、大容量纯化系统等），为国内领先。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":22.88,"timestamp":1788850998000,"preClose":23.43,"halted":0,"volume":33685605,"delay":0,"changeRate":-0.0235,"floatShares":745000000,"shares":883000000,"eps":0.1447,"marketStatus":"已收盘","change":-0.55,"latestTime":"09-08 15:00:00","open":23.51,"high":23.58,"low":22.81,"amount":775000000,"amplitude":0.0329,"askPrice":22.89,"askSize":70,"bidPrice":22.88,"bidSize":471,"shortable":0,"etf":0,"ttmEps":0.1447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":5,"adr":0,"adjPreClose":23.43,"symbolType":"stock","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":25.77,"lowLimit":21.09,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":24.34,"roa":"--","peRate":158.120249,"roe":"32.33%","epsLYR":0.04,"committee":0.838059,"marketValue":20209000000,"turnoverRate":0.0452,"status":1,"floatMarketCap":17039000000},"requestUrl":"/m/hq/s/300199/","defaultTab":"news","newsList":[{"id":"2665132946","title":"翰宇药业（300199）披露全资子公司卡前列素氨丁三醇注射液获得药品注册证书，9月8日股价下跌2.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132946","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665132946?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:53","pubTimestamp":1788861203,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，翰宇药业报收于22.88元，较前一交易日下跌2.35%，最新总市值为202.09亿元。该股当日开盘23.51元，最高23.58元，最低22.81元，成交额达7.75亿元，换手率为4.52%。翰宇药业当日发布公告称，公司全资子公司甘肃成纪生物药业有限公司近日收到国家药品监督管理局签发的卡前列素氨丁三醇注射液《药品注册证书》，药品注册分类为化学药品4类，视为通过仿制药质量和疗效一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800027822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0028","BK0188","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318933","title":"翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665318933?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:51","pubTimestamp":1788771112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，公司全资子公司甘肃成纪生物药业有限公司(以下简称“成纪药业”)于近日收到国家药品监督管理局签发的卡前列素氨丁三醇注射液《药品注册证书》。卡前列素氨丁三醇注射液为前列腺素类药物，主要用于治疗因宫缩乏力所致的产后出血，是临床常用的产后止血药物。本次卡前列素氨丁三醇注射液获得药品注册证书，丰富了公司及子公司成纪药业在妇产科领域的产品管线，有利于提升公司在妇科止血类药物市场的竞争力。公司将按照相关要求尽快推进该产品的上市销售工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","300199","BK0028","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681814","title":"翰宇药业：多肽原料药产能计划本年度内达到10吨级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681814?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:51","pubTimestamp":1788353492,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业09月01日在投资者关系平台上答复投资者关心的问题。武汉的产能规划是否达成预期？按照券商研报显示,片剂的用量会是针剂原料药用量的50-90倍。关于公司多肽原料药产能正在按需扩产中，计划本年度内达到10吨级，同时根据公司战略发展规划结合GLP-1市场的蓬勃发展，预计在2027年扩产至20吨级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200040551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0239","300199","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664145778","title":"翰宇药业：公司产品布局会综合市场环境、供需情况、投入产出、业务战略方向等多重因素审慎考量","url":"https://stock-news.laohu8.com/highlight/detail?id=2664145778","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664145778?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:51","pubTimestamp":1788353488,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)09月01日在投资者关系平台上答复投资者关心的问题。投资者提问：最近新冠病毒又是上升趋势，之前贵司的翰卫和翰护的新冠防护功能较为有效，为什么不继续生产和升级呢？建议继续生产和升级，满足广大人民群众的公共健康安全需求，谢谢！翰宇药业回复：尊敬的投资者，您好！感谢您提出宝贵建议。公司产品布局会综合市场环境、供需情况、投入产出、业务战略方向等多重因素审慎考量。我们会认真吸纳您的建议，结合公司实际业务情况综合评估。公司重大产品相关调整，如涉及信息披露事项将及时公告。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200040547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300199","BK0188","BK0070","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664281458","title":"翰宇药业：持续深耕GLP-1类降糖与减重相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2664281458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664281458?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:48","pubTimestamp":1788353302,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业09月01日在投资者关系平台上答复投资者关心的问题。公司长期专注于多肽药物领域，核心布局 GLP-1 类降糖与减重相关产品，持续深耕该赛道的技术研发与商业化推进。公司会持续跟踪行业前沿科研进展，同时立足自身业务优势，稳步推进现有产品的技术迭代与管线拓展，夯实核心竞争力。行业发展存在诸多变量，提请广大投资者理性看待，注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200040421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300199","BK0239","BK0028","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814302","title":"翰宇药业：持续跟踪行业形势变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664814302?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:48","pubTimestamp":1788353301,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业09月01日在投资者关系平台上答复投资者关心的问题。大家对新冠防护还是有很大需求的，谢谢翰宇药业回复：尊敬的投资者，您好！公司高度重视相关市场动态与公共卫生需求，会持续跟踪行业形势变化，结合自身业务定位、技术储备与经营实际开展充分的调研论证，审慎评估相关产品的研发及生产规划，适时统筹考虑各方合理建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200040417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0188","300199","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664153088","title":"翰宇药业(300199.SZ)：坪山分公司通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2664153088","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664153088?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:52","pubTimestamp":1788346359,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司坪山分公司于2026年6月18日至26日接受了美国食品药品监督管理局的现行药品生产质量管理规范常规监督检查。近日，公司收到了FDA签发的现场检查报告。此次检查是坪山分公司继2023年7-8月首次通过FDA批准前检查后，第二次接受FDA检查并顺利通过。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0028","300199","LABU","BK0239","BK0077","BK0188","BK0070","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664130748","title":"翰宇药业：坪山分公司第二次通过FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2664130748","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664130748?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:46","pubTimestamp":1788346015,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0188","BK0077","BK0070","300199","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661726902","title":"翰宇药业(300199)6月30日股东户数6.73万户，较上期减少31.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661726902","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661726902?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:46","pubTimestamp":1787305588,"startTime":"0","endTime":"0","summary":"证券之星消息，近日翰宇药业披露，截至2026年6月30日公司股东户数为6.73万户，较3月31日减少3.15万户，减幅为31.87%。在化学制药行业个股中，翰宇药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年3月31日至2026年6月30日，翰宇药业区间涨幅为16.95%，在此期间股东户数减少3.15万户，减幅为31.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0239","BK0188","BK0028","BK0070","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284070","title":"翰宇药业最新公告：2026年半年度净利润同比增长62.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284070","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660284070?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:40","pubTimestamp":1787229622,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司发布2026年半年度报告，实现营业收入6.88亿元，同比增长25.27%；归属于上市公司股东的净利润2.37亿元，同比增长62.72%。公司计划不派发现金红利，不送红股，不以公积金转增股本。注：公司Q2净利润1.09亿，Q1净利润1.28亿，据此计算，Q2净利润环比下降14%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000041495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284245","title":"翰宇药业：利拉鲁肽注射液获新加坡卫生科学局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284245","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660284245?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:36","pubTimestamp":1787229366,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300199","BK0239","BK0188","BK0028","BK0070","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979350","title":"翰宇药业最新公告：与三生蔓迪签署司美格鲁肽注射液（血糖控制适应症）合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979350","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658979350?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:31","pubTimestamp":1786530683,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司与三生蔓迪签署司美格鲁肽注射液(血糖控制适应症)合作协议，授予三生蔓迪在中国区域(中国大陆、香港、澳门)的独占商业化许可。合作财务条款包括签约首付款1200万元、注册及商业化里程碑付款以及销售提成。本次合作将深化双方在GLP-1类多肽药物领域的布局，对公司未来经营业绩产生积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200033273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0188","300199","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657664172","title":"翰宇药业（300199）披露替尔泊肽注射液首仿上市申请获得受理的公告，8月7日股价上涨8.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657664172","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657664172?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:04","pubTimestamp":1786111499,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，翰宇药业报收于24.38元，较前一交易日上涨8.45%，最新总市值为215.33亿元。近日，深圳翰宇药业股份有限公司收到国家药品监督管理局签发的替尔泊肽注射液《受理通知书》，申请事项为境内生产药品注册上市许可，注册分类为化学药品4类，适应症包括2型糖尿病、长期体重管理和阻塞性睡眠呼吸暂停。替尔泊肽为GLP-1R/GIPR双靶点激动剂，全球尚无仿制药上市，翰宇药业为国内首家提出上市许可申请的企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700040515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0239","300199","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616807","title":"翰宇药业：替尔泊肽注射液首仿上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616807","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616807?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:44","pubTimestamp":1786092284,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0070","BK0028","BK0188","300199","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655807291","title":"股市必读：翰宇药业（300199）新发布《关于HY3003多肽创新药临床前药效学研究结果的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655807291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655807291?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:58","pubTimestamp":1785434293,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，翰宇药业报收于20.2元，下跌2.13%，换手率4.9%，成交量36.54万手，成交额7.56亿元。公司公告汇总：翰宇药业宣布HY3003注射液完成临床前药效学研究，在DIO小鼠模型中减重效果优于替尔泊肽和瑞他曲肽。公司公告汇总关于HY3003多肽创新药临床前药效学研究结果的公告深圳翰宇药业股份有限公司公告，其自主研发的GLP-1/GIP/GCGR三重受体激动剂HY3003注射液已完成临床前药效学研究。该研究结果支持HY3003作为潜在代谢类疾病治疗药物的开发前景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0239","BK1161","BK1574","300199","BK0188","159992","06978","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861830","title":"翰宇药业(300199.SZ)：HY3003注射液已完成临床前动物药效学研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861830","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655861830?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:40","pubTimestamp":1785321601,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 翰宇药业 发布公告，近日，公司取得了《HY3003注射液经皮下注射给予DIO小鼠多次给药药效学预试验总结报告》及《HY3003注射液经皮下注射给予DIO小鼠多次给药药效学试验总结报告》。报告显示，公司开发的新一代GLP-1/GIP/GCGR三重受体激动剂HY3003注射液，已完成临床前动物药效学研究。本次临床前药效学研究结果验证了HY3003在三靶点代谢药物领域的差异化药效优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0077","BK0239","300199","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652286708","title":"翰宇药业（300199）披露向激励对象首次授予限制性股票的公告，7月17日股价下跌12.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652286708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652286708?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:09","pubTimestamp":1784297358,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，翰宇药业报收于21.44元，较前一交易日下跌12.38%，最新总市值为189.37亿元。近日，深圳翰宇药业股份有限公司披露《关于向激励对象首次授予限制性股票的公告》。公告显示，公司于2026年7月17日向111名激励对象首次授予1,735.00万股限制性股票，授予价格为11.61元/股，股票来源为公司自二级市场回购和/或定向增发的A股普通股。本激励计划为第二类限制性股票，有效期最长不超过60个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0188","BK0077","BK0028","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651626117","title":"翰宇药业（300199）披露2026年限制性股票激励计划内幕信息知情人买卖公司股票情况自查报告，7月13日股价下跌7.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651626117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651626117?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:05","pubTimestamp":1783951524,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，翰宇药业报收于23.5元，较前一交易日下跌7.63%，最新总市值为207.56亿元。该股当日开盘25.03元，最高25.44元，最低23.37元，成交额达14.32亿元，换手率为7.97%。近日，翰宇药业发布《关于2026年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告》。经向中国证券登记结算有限责任公司深圳分公司查询，所有内幕信息知情人在自查期间均不存在买卖公司股票的行为。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300039789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0188","BK0070","BK0239","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135507","title":"翰宇药业（300199）披露2026年半年度业绩预告，7月10日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650135507?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:11","pubTimestamp":1783692678,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，翰宇药业报收于25.44元，较前一交易日下跌1.32%，最新总市值为224.7亿元。近日，深圳翰宇药业股份有限公司发布2026年半年度业绩预告，预计2026年1月1日至6月30日营业收入为68,000.00万元至70,000.00万元，同比增长23.76%-27.40%；归属于上市公司股东的净利润为22,500.00万元至24,500.00万元，同比增长54.67%-68.42%；扣除非经常性损益后的净利润为21,700.00万元至23,700.00万元，同比增长75.88%-92.09%。该数据未经会计师事务所审计，最终数据以2026年半年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0070","BK0188","BK0028","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650818660","title":"翰宇药业最新公告：预计2026年半年度净利润同比增长54.67%-68.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650818660","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650818660?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:23","pubTimestamp":1783675392,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，预计2026年半年度归属于上市公司股东的净利润为2.25亿元-2.45亿元，同比增长54.67%-68.42%。业绩变动主要系原料药业务持续放量，带来营收、利润双增长，同时财务精细化管理水平提升，费用管控合理。注：公司Q2净利润预计0.97亿-1.17亿，Q1净利润1.28亿，据此计算，Q2净利润预计环比下降8%-23%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788882456239,"stockEarnings":[{"period":"1week","weight":0.0205},{"period":"1month","weight":-0.039},{"period":"3month","weight":0.0933},{"period":"6month","weight":0.2966},{"period":"1year","weight":-0.0602},{"period":"ytd","weight":0.3089}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0193},{"period":"6month","weight":-0.0486},{"period":"1year","weight":0.0315},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"67294人(较上一季度减少31.87%)","perCapita":"11066股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。公司共获得国内专利四百余项，国际专利数十项，各类多肽药物批件、新药证书和临床批件，配备国际领先的研发实验室及300余台（套）高端设备（如全自动合成系统、大容量纯化系统等），为国内领先。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}